Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Abstracts of the 16th International Charles Heidelberger Symposium on Cancer Research

Open Access Poster presentation

Melanoma skin cancer: could chromone derivatives be efficient chemopreventors?

Mafalda M Dias1* and Maria PM Marques12

Author Affiliations

1 Research Unit “Molecular Physical Chemistry”, University of Coimbra, Coimbra, Portugal

2 Department of Life Sciences, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal

For all author emails, please log on.

BMC Proceedings 2010, 4(Suppl 2):P28  doi:10.1186/1753-6561-4-S2-P28

The electronic version of this article is the complete one and can be found online at:

Published:24 September 2010

© 2010 Dias et al; licensee BioMed Central Ltd.

Poster presentation

Melanoma is a highly metastatic tumour and its incidence has ranked 5th and 6th among the most common cancer afflicting both men and women. Melanoma cells have a diminished antioxidant potential compared to normal melanocytes, which leads to an accumulation of ROS [1]. 1,4-benzopyrone heterocyclic compounds are widely distributed in plants and are reported to exhibit several biological roles, including antioxidant and free radical scavenging [2], displaying a variety of pharmacological properties such as anti-inflammatory and antitumour [3]. The present study aimed to assess the response of the melanotic human skin melanoma (A375) cell line to treatment with 8 different benzopyran derivatives (eg. fisetin, luteolin and quercetin) - in the concentration range 12.5 - 100µM, for 24, 48 and 72h incubation periods (using the MTT assay). Reversibility of the drug effect (after 3 days) was also tested. Concomitantly, similar experiments were carried out for non-neoplasic, non-immortalised, human foreskin fibroblasts (BJ).

The results thus gathered allowed to conclude that the chromone derivatives are promising chemopreventive and/or chemotherapeutic agents towards melanoma, while having no considerable adverse effect against healthy cells.


  1. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL Jr: Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol.

    Mol Cancer Ther 2008, 7:3751-3760. PubMed Abstract | Publisher Full Text OpenURL

  2. Okawa M, Kinjo J, Nohara T, Ono M: DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants.

    Biol Pharm Bull 2001, 24:1202-1205. PubMed Abstract | Publisher Full Text OpenURL

  3. Pietta PG: Flavonoids as Antioxidants.

    J Nat Prod 2000, 63:1035-1042. PubMed Abstract | Publisher Full Text OpenURL